首页> 美国卫生研究院文献>Cell Death Disease >Withaferin-A kills cancer cells with and without telomerase: chemical computational and experimental evidences
【2h】

Withaferin-A kills cancer cells with and without telomerase: chemical computational and experimental evidences

机译:Withaferin-A可以在有或没有端粒酶的情况下杀死癌细胞:化学计算和实验证据

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Maintenance of telomere length is the most consistent attribute of cancer cells. Tightly connected to their capacity to overcome replicative mortality, it is achieved either by activation of telomerase or an Alternative mechanism of Lengthening of Telomeres (ALT). Disruption of either of these mechanisms has been shown to induce DNA damage signalling leading to senescence or apoptosis. Telomerase inhibitors are considered as potential anticancer drugs but are ineffective for ALT cancers (~15% of all cancers). Withaferin-A (Wi-A), a major constituent of the medicinal plant, Withania somnifera (Ashwagandha), has been shown to exert anti-tumour activity. However, its effect on either telomerase or ALT mechanisms has not been investigated. Here, by using isogenic cancer cells with/without telomerase, we found that Wi-A caused stronger cytotoxicity to ALT cells. It was associated with inhibition of ALT-associated promyelocytic leukemia nuclear bodies, an established marker of ALT. Comparative analyses of telomerase positive and ALT cells revealed that Wi-A caused stronger telomere dysfunction and upregulation of DNA damage response in ALT cells. Molecular computational and experimental analyses revealed that Wi-A led to Myc-Mad mediated transcriptional suppression of NBS-1, an MRN complex protein that is an essential component of the ALT mechanism. The results suggest that Wi-A could be a new candidate drug for ALT cancers.
机译:端粒长度的维持是癌细胞最一致的属性。通过克服端粒酶的激活或端粒延长的替代机制(ALT),可以实现其克服复制性死亡的能力。这些机制中任何一个的破坏都已显示出诱导DNA损伤的信号,导致衰老或凋亡。端粒酶抑制剂被认为是潜在的抗癌药物,但对ALT癌症无效(占所有癌症的15%)。 Withaferin-A(Wi-A)是药用植物Withania somnifera(Ashwagandha)的主要成分,具有抗肿瘤活性。但是,尚未研究其对端粒酶或ALT机制的影响。在这里,通过使用具有/不具有端粒酶的等基因癌细胞,我们发现Wi-A对ALT细胞产生更强的细胞毒性。它与抑制ALT相关的早幼粒细胞白血病核体(一种已建立的ALT)有关。端粒酶阳性细胞和ALT细胞的比较分析表明,Wi-A引起更严重的端粒功能障碍和ALT细胞DNA损伤反应的上调。分子计算和实验分析表明,Wi-A导致Myc-Mad介导的NBS-1(一种MRN复杂蛋白,是ALT机制的重要组成部分)介导的转录抑制。结果表明,Wi-A可能是ALT癌症的新候选药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号